As the year comes to a close, we would like to recognize all of the people who have contributed to the growth and continued success of Contemporary OB/GYN.
Catherine Y. Spong, MD
Since joining Contemporary OB/GYN in April as Editor-in-Chief, Catherine Y. Spong, MD has gracefully and skillfully led our team through a year no one saw coming.
Jon I. Einarsson, MD, MPH, PHD
Thank you to our Deputy Editor, Jon I. Einarsson, MD, MPH, PHD, for his continued support and valuable contributions.
Thank you to the esteemed members of our Editorial Advisory Board; We appreciate all of the work you do. We would also like to recognize the Board’s newest members who joined with enthusiasm, despite a global pandemic: Yalda Afshar, MD, PHD, Christine Isaacs, MD, and Laura Riley, MD. Welcome to the team!
Thank you to former Editorial Advisory Board member Sharon T. Phelan, MD, for her keen insights and expertise, and to Judith M. Orvos, long-time editorial consultant, whose contributions have helped shape the magazine into what it is today.
We are excited to begin another year with such a distinguished team behind us, and with you, our readers, to join the conversation as learners, practitioners and educators. We are eager to begin another wonderful year with you.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More